Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses
- 5 October 2024
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116941
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in miceActa Pharmaceutica Sinica B, 2024
- Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profilesEuropean Journal of Medicinal Chemistry, 2023
- Discovery of novel 1,2,4‐triazole phenylalanine derivatives targeting an unexplored region within the interprotomer pocket of the HIV capsid proteinJournal of Medical Virology, 2022
- Approved HIV reverse transcriptase inhibitors in the past decadeActa Pharmaceutica Sinica B, 2021
- Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like propertiesEuropean Journal of Medicinal Chemistry, 2021
- Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty yearsActa Pharmaceutica Sinica B, 2020
- Molecular design opportunities presented by solvent‐exposed regions of target proteinsMedicinal Research Reviews, 2019
- Challenges and approaches in the discovery of human immunodeficiency virus type‐1 non‐nucleoside reverse transcriptase inhibitorsMedicinal Research Reviews, 2018
- Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocketEuropean Journal of Medicinal Chemistry, 2016
- Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptaseJournal of Virological Methods, 1993